Skip to content

Study on the effect of cipofol combined with remazolam intravenous anesthesia in painless gastroscopy

The impact of intravenous anesthesia with cipofol on postoperative recovery quality in patients: a prospective, single center, double-blind, randomized controlled clinical study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079998
Enrollment
Unknown
Registered
2024-01-18
Start date
2024-02-01
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive tract disease

Interventions

Propofol group:Intravenous injection of propofol 1mg/kg sedation
ciprofol and remimazolam group:ciprofol 0.2mg/kg+ remimazolam 0.1mg/kg was injected intravenously for sedation
ciprofol group:Intravenous injection of ciprofol 0.4mg/kg sedation

Sponsors

General Hospital of the PLA Center War Zone
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: Patients planning to undergo painless gastroscopy examination; Age: 18-79 years old, BMI 18-28 kg/m ²; The American Society of Anesthesiologists (ASA) classifies patients into grades I to III.

Exclusion criteria

Exclusion criteria: Persons with mental illness; Patients with previous cognitive dysfunction; Have a history of allergy to the drugs used in this study; People with severe organ dysfunction such as heart, lung, liver and kidney; Have a history of alcohol or drug abuse within 3 months of the perioperative period or the examination period

Design outcomes

Primary

MeasureTime frame
Recovery time;Incidence of hypotension;recovery quality;

Secondary

MeasureTime frame
Induction time;Supplementary drug frequency;Patient satisfaction;Endometrist satisfaction;Total amount of sedatives used;Adverse reactions;Departure time;

Countries

China

Contacts

Public ContactZHOU XIANG

General Hospital of the PLA Center War Zone

zhouxiang188483@126.com+86 186 2771 8483

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026